Borrelia burgdorferi Antibody, IgG by Immunoblot
Ordering Recommendation
Do not order in the absence of a positive or equivocal first-tier screening test for Lyme disease.
Second-tier testing for use >4 weeks after symptom onset.
New York DOH Approval Status
Specimen Required
Serum separator tube.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum to an ARUP Standard Transport Tube. (Min: 0.1 mL)
Refrigerated.
CSF or plasma. Contaminated, heat-inactivated, severely hemolyzed, severely lipemic, and severely icteric specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid repeated freeze/thaw cycles)
Methodology
Qualitative Immunoblot
Performed
Sun-Sat
Reported
1-4 days
Reference Interval
Test Number |
Components |
Reference Interval |
---|---|---|
B. burgdorferi IgG Immunoblot | Negative |
Interpretive Data
For this assay, a positive result is reported when any 5 or more of the following 10 bands are present: 18, 23, 28, 30, 39, 41, 45, 58, 66, or 93 kDa. All other banding patterns are reported as negative.
FDA
Note
This test should be used for confirmation of an equivocal or positive B. burgdorferi Total Antibodies, IgG and/or IgM test performed on patients greater than 4 weeks after disease onset. A negative result indicates that the immunoblot evaluation for the Lyme antibody demonstrates no antibodies unique to B. burgdorferi and is, therefore, not supportive of Lyme disease.
A positive result indicates that the immunoblot evaluation for B. burgdorferi antibody is consistent with the presence of antibody produced by patients in response to infection by B. burgdorferi and suggests the presence of Lyme disease. Although the test has been shown to have a high degree of reliability for diagnostic purposes, laboratory data should always be correlated with clinical findings.
Current CDC recommendations for the serological diagnosis of Lyme disease are to screen with a polyvalent ELISA test and confirm equivocals and positives with immunoblot. Both IgM and IgG immunoblots should be performed on samples obtained less than 4 weeks after appearance of erythema migrans. Only IgG immunoblot is to be performed on samples greater than 4 weeks after disease onset. IgM immunoblot in the chronic stage is not recommended and does not aid in the diagnosis of neuroborreliosis or chronic Lyme disease.
Hotline History
Hotline History
CPT Codes
86617
Components
Component Test Code* | Component Chart Name | LOINC |
---|---|---|
0050252 | B. burgdorferi IgG Immunoblot | 6320-6 |
Aliases
- Lyme Antibody
- Lyme Disease IgG WB
- Lyme Disease
- Lyme Disease IgG Western Blot